Pediatric Hematology/Oncology

TTP

Questions discussed in this category

How do you approach a patient with chronic low ADAMTS13 activity and low level of inhibitor without signs of thrombocytopenia or hemolysis?

ADAMTS13 level <5% Inhibitor level <1

1 Answer available

How do you explain TTP to patients?

1 Answer available

Papers discussed in this category

Blood, 2018 Sep 10

Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura.

Related Topics in Pediatric Hematology/Oncology